2020 年法国长期接受羟氯喹治疗的类肉瘤病患者中的 COVID-19 病例。
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020.
出版信息
Emerg Infect Dis. 2020 Oct;26(10):2513-2515. doi: 10.3201/eid2610.201816. Epub 2020 Jul 1.
Abstract
Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
摘要
由于体外研究，羟氯喹已被评估为用于冠状病毒病（COVID-19）的暴露前或暴露后预防，以及可能用于 COVID-19 的治疗。我们报告了一例 COVID-19 病例，患者患有结节病，正在长期接受羟氯喹治疗，尽管血浆浓度足够，但仍感染了 COVID-19。
Zotero 插件